What question did this study set out to answer?

The study aimed to explore whether Isoquercetin could mitigate muscle atrophy associated with obesity.

April 8, 2026

Isoquercetin Ameliorates Obesity-Associated Muscle Atrophy and Modulates the Gut Microbiota–Bile Acid Axis

Key Points

The study aimed to explore whether Isoquercetin could mitigate muscle atrophy associated with obesity.
Utilized a mouse model of high-fat diet-induced obesity.
Administered Isoquercetin and compared effects with a vehicle group.
Measured grip strength, exercise capacity, and skeletal muscle mass.
Analyzed insulin signaling, protein synthesis, and mitochondrial function pathways.
Evaluated changes in gut inflammation and microbiota composition.
Isoquercetin treatment improved grip strength by over 45.5%.
Increased exercise capacity was noted at >17.1%.
Skeletal muscle mass enhanced by >34.5%.
Reduced colon inflammation and gut permeability were observed.
Significant modulation of gut microbial community and bile acids was achieved.

Abstract

Obesity-associated muscle atrophy poses a significant health challenge. Isoquercetin (IQ) exhibits potent anti-inflammatory, antioxidant, and metabolic regulatory effects; however, whether IQ can attenuate this condition remains elusive. Thus, we employed a mouse model of HFD-induced obesity-associated muscle atrophy to assess its therapeutic potential. Compared to the HFD vehicle group, IQ treatment enhanced grip strength (>45.5%, p 17.1%, p 34.5%, p p p IL-1β) and gut barrier permeability (1.66-fold lower of ZO-1), as well as reshaped gut microbial community and modulated bile acid composition in obese mice. Overall, these results provide novel evidence that IQ supplementation has the potential for mitigating obesity-related muscle atrophy.

AI에게 질문

Bookmark

Cite This Study

Song et al. (Sun,) studied this question.

synapsesocial.com/papers/69d5f07d74eaea4b11a79e67 https://doi.org/https://doi.org/10.1021/acs.jafc.5c16221

AI에게 질문

Bookmark